24 results about "Integrase inhibitor" patented technology

The present disclosure relates generally to solid forms of the compound of Formula I:Also disclosed are pharmaceutical compositions comprising said solid forms and methods of making said solid forms. The solid forms of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)— or the like: each R1 independently represents a halogen atom or the like: each of R2a and R2b independently represents a hydrogen atom or the like: R3 represents an alkyl group or a haloalky 1 group: R4 represents a hydrogen atom or an alkyl group: and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof, and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable liquid vehicle. Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) in a human, including administering to the human a pharmaceutical composition disclosed herein.

The invention relates to a pyridone derivative as shown in a formula (I) or a stereoisomer thereof, a prodrug of the pyridone derivative, a pharmaceutically acceptable salt, a pharmaceutical composition containing the formula (I), and application of the pyridone derivative or the stereoisomer thereof, the prodrug of the pyridone derivative, the pharmaceutically acceptable salt and the pharmaceutical composition in preparation of a medicine for preventing and / or treating HIV (Human Immunodeficiency Virus) infection. The compound disclosed by the invention has remarkable anti-HIV virus activity, relatively low solubility and very low clearance rate, is suitable for developing a long-acting injection prevention and treatment scheme, and is used for preparing a medicine of an HIV virus integrase inhibitor or a medicine composition containing the medicine so as to benefit patients infected by HIV viruses.

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)—or the like; each R1 independently represents a halogen atom or the like; each of R1a and R1b independently represents a hydrogen atom or the like, R2represents an alkyl group or a haloalkyl group, R3represents a hydrogen atom or an alkyl group; and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof; and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

The present disclosure relates generally to solid forms of the compound of Formula I: Also disclosed are pharmaceutical compositions comprising said solid forms and methods of making said solid forms. The solid forms of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

A composition comprising a stable colloid of an HIV integrase inhibitor for the preparation of an injectable, long-acting pharmaceutical product for treating and preventing HIV infection.

The present invention relates to hydroxyl-substituted fused tetracyclic heterocycle compounds, including a compound of formula (1): and pharmaceutically acceptable salts thereof, which compounds exhibit activity against HIV integrase. The present invention also relates to compositions comprising these compounds, and methods of making these compounds. The invention further relates to methods of using these compounds for treating HIV infection in a subject, including administering these compounds once-weekly for treatment of HIV infection.

Disclosed are a compound of Formula I, stereoisomers, pharmaceutically acceptable salts and deuterated compounds thereof and a method for treating, inhibiting and / or preventing a disease or disorder in a subject in need thereof: wherein A, R, G, Y and n are defined as in the present disclosure.

The invention provides an application of an anti-HIV (human immunodeficiency virus) pharmaceutical composition in immune improvement, in particular to an application of the HIV pharmaceutical composition in preparation of a medicine for immune regulation, the medicine for immune regulation is a medicine for carrying out immune regulation on HIV-1 infected people inhibited by viruses, and the anti-HIV pharmaceutical composition comprises an HIV fusion inhibitor and an HIV integrase inhibitor, the infected person is the infected person treated by an ART scheme. Experiments show that the pharmaceutical composition has a good antiviral effect and safety, and has a very good effect on immune reconstruction of patients.

Compounds of Formula I, stereoisomers, pharmaceutically acceptable salts, and deuterated compounds thereof: wherein A, R, G, Y, and n are as defined herein, and methods of treating, inhibiting, and / or preventing a disease or disorder in a subject in need thereof are disclosed.

The present invention relates to tetracyclic heterocyclic compounds of Formula (I): and pharmaceutically acceptable salts or prodrugs thereof, wherein R 1 as defined herein. The present invention also relates to compositions comprising at least one tetracyclic heterocyclic compound and methods of using the tetracyclic heterocyclic compounds to treat or prevent HIV infection in a subject.

To provide pharmaceuticals useful for the prevention or treatment of HIV infection.SOLUTION: Provided is a pharmaceutical for preventing or treating HIV infection, comprising: (A) a compound represented by formula (I): (where, ring A is a non-aromatic heterocycle; ring B is a benzene ring or a pyridine ring; Q is -NHC(O)- or the like; R1 is each independently halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is alkyl or haloalkyl; R4 is hydrogen or alkyl; and n is an integer of 1 to 3), or a pharmaceutically acceptable salt thereof, in combination with (B) a compound having anti-HIV activity or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None

The present disclosure relates generally to pharmaceutical compositions (e.g., solid oral dosage forms) of the compound of Formula I:Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) infection in a human, including orally administering to the human the solid oral dosage forms or pharmaceutical compositions disclosed herein.

The present disclosure relates generally to pharmaceutical compositions (e.g., solid oral dosage forms) of the compound of Formula I: Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) infection in a human, including orally administering to the human the solid oral dosage forms or pharmaceutical compositions disclosed herein.

The invention relates to a polymorphic substance of a pyrrolopyridine derivative and a preparation method of the polymorphic substance. The polymorphic substance is used as a non-catalytic site integrase inhibitor. The novel polymorph of the present invention exhibits excellent non-hygroscopicity and stability, and thus is suitable for use in pharmaceutical formulations.

The present invention pertains to: a polymorph of a pyrrolopyridine derivative which is a non-catalytic site integrase inhibitor; and a method for producing same. The novel polymorph of the present invention exhibits excellent non-hygroscopicity and stability and is thus suitable for pharmaceutical preparations.

The invention relates to antiviral prodrugs and nanoformulations thereof. The present invention provides prodrugs and methods of using the same. The present application provides a compound or a pharmaceutically acceptable salt thereof comprising a first integrase inhibitor and a second integrase inhibitor wherein the first integrase inhibitor and the second integrase inhibitor are covalently attached by a linker. The present application also provides a compound or a pharmaceutically acceptable salt thereof comprising an integrase inhibitor conjugated to an amino acid fatty ester wherein the amino acid fatty ester comprises an aliphatic group or a hydrocarbyl group.

The present disclosure relates generally to solid forms of the compound of Formula I: Also disclosed are pharmaceutical compositions comprising said solid forms and methods of making said solid forms. The solid forms of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I:or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable liquid vehicle.Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) in a human, including administering to the human a pharmaceutical composition disclosed herein.